inato | CASE STUDY

Portfolio Collaboration

Background

Due to the continuing COVID-19 pandemic, a large, global sponsor was facing challenges in their trials. They partnered with Inato to access a broader variety of patient populations and boost the efficacy of their studies.

The Problem

Like many sponsors, the pandemic presented a number of new obstacles for their team. With competition increasing in academic research centers already, the added challenge of a decrease in patients visiting their doctors and reporting illness as a result of the pandemic contributed heavily to their decision to seek out alternative options.

The sponsor wanted access to a broader patient population in order to speed up trial timelines, meet diversity goals, and patch up the delays brought on by COVID-19 but didn't have a way to identify reliable research centers with the patient demographics their trials called for.

By posting the trial information across trials, the sponsor allows sites to show interest in the ones best for them & their patients.



The Solution

From Q4 of 2020, the sponsor posted eight trials to Inato's platform across a number of disease areas including Multiple Sclerosis, Asthma, and Chronic Obstructive Pulmonary Disease. Sites in Inato's network from across the globe were able to view the study descriptions and express interest in those they had the patients and resources to execute. Inato worked closely with each site to understand their capabilities and identify which ones would be the best fit for each trial. With detailed profiles of the community-based sites and an iterative estimate of the patients each research center could recruit, Inato recommended sites to the sponsor. This process allowed them to choose sites they knew they could trust with the experience, resources, and patients necessary to meet their trial goals. Additionally, it accelerated start up timelines with two patients in the RMS trial screened within the first week of activation.

"This is really allowing us to target sites with access to exact patient populations we need for these studies, allowing us to have better predictability around our diversity targets."

—

HEAD, CLINICAL PROJECT OPERATIONS

The Results

BY FEBRUARY OF 2022:

8 Studies launched since Q4 2020

2 Studies using Inato's Inclusive Research Program for diversity

9 Countries with selected sites to date

47
SITES SELECTED BY THE SPONSOR TO DATE

Using Inato's verified commitment, these sites have already proven their ability to recruit patients meeting the inclusion criteria, including:

124	70	48
MS patients	COPD patients	Asthma patients

Don't wait to start improving your trial outcomes. Reach out today.

EMAIL CONTACT@INATO.COM